CY1114497T1 - ΜΕΘΟΔΟΙ ΚΑΙ ΣΥΝΘΕΣΕΙΣ ΓΙΑ ΤΗΝ ΑΝΤΙΜΕΤΩΠΙΣΗ ΚΑΙ ΤΗΝ ΠΡΟΛΗΨΗ ΝΟΣΟΥ ΠΟΥ ΣΧΕΤΙΖΕΤΑΙ ΜΕ ΤΗΝ ΙΝΤΕΓΚΡΙΝΗ ανβ5 - Google Patents

ΜΕΘΟΔΟΙ ΚΑΙ ΣΥΝΘΕΣΕΙΣ ΓΙΑ ΤΗΝ ΑΝΤΙΜΕΤΩΠΙΣΗ ΚΑΙ ΤΗΝ ΠΡΟΛΗΨΗ ΝΟΣΟΥ ΠΟΥ ΣΧΕΤΙΖΕΤΑΙ ΜΕ ΤΗΝ ΙΝΤΕΓΚΡΙΝΗ ανβ5

Info

Publication number
CY1114497T1
CY1114497T1 CY20131100713T CY131100713T CY1114497T1 CY 1114497 T1 CY1114497 T1 CY 1114497T1 CY 20131100713 T CY20131100713 T CY 20131100713T CY 131100713 T CY131100713 T CY 131100713T CY 1114497 T1 CY1114497 T1 CY 1114497T1
Authority
CY
Cyprus
Prior art keywords
prevention
treatment
methods
compositions
integrity
Prior art date
Application number
CY20131100713T
Other languages
Greek (el)
English (en)
Inventor
Dean Sheppard
Amha Atakilit
Original Assignee
The Regents Of The University Of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Regents Of The University Of California filed Critical The Regents Of The University Of California
Publication of CY1114497T1 publication Critical patent/CY1114497T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
CY20131100713T 2004-04-02 2013-08-21 ΜΕΘΟΔΟΙ ΚΑΙ ΣΥΝΘΕΣΕΙΣ ΓΙΑ ΤΗΝ ΑΝΤΙΜΕΤΩΠΙΣΗ ΚΑΙ ΤΗΝ ΠΡΟΛΗΨΗ ΝΟΣΟΥ ΠΟΥ ΣΧΕΤΙΖΕΤΑΙ ΜΕ ΤΗΝ ΙΝΤΕΓΚΡΙΝΗ ανβ5 CY1114497T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55917504P 2004-04-02 2004-04-02
EP05763460.2A EP1734996B1 (en) 2004-04-02 2005-03-30 Methods and compositions for treating and preventing disease associated with alpha v beta 5 integrin

Publications (1)

Publication Number Publication Date
CY1114497T1 true CY1114497T1 (el) 2016-10-05

Family

ID=35064346

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20131100713T CY1114497T1 (el) 2004-04-02 2013-08-21 ΜΕΘΟΔΟΙ ΚΑΙ ΣΥΝΘΕΣΕΙΣ ΓΙΑ ΤΗΝ ΑΝΤΙΜΕΤΩΠΙΣΗ ΚΑΙ ΤΗΝ ΠΡΟΛΗΨΗ ΝΟΣΟΥ ΠΟΥ ΣΧΕΤΙΖΕΤΑΙ ΜΕ ΤΗΝ ΙΝΤΕΓΚΡΙΝΗ ανβ5

Country Status (14)

Country Link
US (2) US20050226865A1 (enExample)
EP (2) EP2394662B1 (enExample)
JP (2) JP5223072B2 (enExample)
CN (1) CN1964740A (enExample)
AU (1) AU2005229015C1 (enExample)
CA (1) CA2562038C (enExample)
CY (1) CY1114497T1 (enExample)
DK (1) DK1734996T3 (enExample)
ES (2) ES2671522T3 (enExample)
HR (1) HRP20130782T1 (enExample)
PL (1) PL1734996T3 (enExample)
PT (1) PT1734996E (enExample)
RS (1) RS52918B (enExample)
WO (1) WO2005094391A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2456460A4 (en) * 2009-07-24 2013-02-20 Univ California METHOD AND COMPOSITIONS FOR TREATING AND PREVENTING DISEASES ASSOCIATED WITH AVB5 INTEGRIN
WO2013181666A2 (en) * 2012-06-01 2013-12-05 Isis Pharmaceuticals, Inc. Antisense compounds targeting genes associated with fibronectin
MX2015011670A (es) * 2013-03-15 2016-03-31 Biogen Ma Inc Tratamiento y prevencion de lesion renal aguda usando anticuerpos anti-alfa v beta 5.
WO2014144616A2 (en) * 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anti-alpha v beta 5 antibodies and uses thereof
EP3021942A4 (en) * 2013-07-19 2017-04-19 The Regents of The University of California Milk fat globule epidermal growth factor 8 regulates fatty acid uptake
MX2017003014A (es) * 2014-09-12 2017-05-30 Biogen Ma Inc Anticuerpos anti-alfa v beta 5 humanizados y usos de estos.
US11339221B2 (en) 2017-11-01 2022-05-24 Tufts Medical Center, Inc. Bispecific antibody constructs and methods of use

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10023A (en) * 1853-09-20 Machine fob sawing sticks eob broom-handles
US171271A (en) * 1875-12-21 Improvement in bob-sleds
US72500A (en) * 1867-12-24 Improvement in bleaceisg and scouring hemp, flax, aid other fibres
US139398A (en) * 1873-05-27 Improvement in lamp-extinguishers
US181440A (en) * 1876-08-22 Improvement in steam-boiler furnaces
US37889A (en) * 1863-03-10 Mode of
US19035A (en) * 1858-01-05 mallary
US19037A (en) * 1858-01-05 Washing-machine
US18192A (en) * 1857-09-15 And samuel m
US19206A (en) * 1858-01-26 Hydrant
US77321A (en) * 1868-04-28 Amos bank
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
WO1987002671A1 (en) 1985-11-01 1987-05-07 International Genetic Engineering, Inc. Modular assembly of antibody genes, antibodies prepared thereby and use
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5010175A (en) 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
IE66205B1 (en) 1990-06-14 1995-12-13 Paul A Bartlett Polypeptide analogs
US5231114A (en) 1990-06-22 1993-07-27 Wakunaga Seiyaku Kabushiki Kaisha Polysulfides compounds and lipid peroxidation inhibitor containing the polysulfide compounds as active ingredient
US5650489A (en) 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
US5527679A (en) * 1991-05-01 1996-06-18 Dana Farber Cancer Institute β5 protein and DNA encoding the same
DE4142366A1 (de) * 1991-07-15 1993-06-24 Thomae Gmbh Dr K Phenylalkylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE4123341A1 (de) * 1991-07-15 1993-01-21 Thomae Gmbh Dr K Phenylalkylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
US5777085A (en) 1991-12-20 1998-07-07 Protein Design Labs, Inc. Humanized antibodies reactive with GPIIB/IIIA
US6291196B1 (en) * 1992-01-31 2001-09-18 Research Corporation Technologies, Inc. Melanoma and prostate cancer specific antibodies for immunodetection and immunotherapy
CA2131389A1 (en) 1992-03-02 1993-09-16 John M. Maraganore Thrombin receptor antagonists
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5288514A (en) 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
US6210671B1 (en) 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5593853A (en) 1994-02-09 1997-01-14 Martek Corporation Generation and screening of synthetic drug libraries
US5539083A (en) 1994-02-23 1996-07-23 Isis Pharmaceuticals, Inc. Peptide nucleic acid combinatorial libraries and improved methods of synthesis
US5525735A (en) 1994-06-22 1996-06-11 Affymax Technologies Nv Methods for synthesizing diverse collections of pyrrolidine compounds
US5549974A (en) 1994-06-23 1996-08-27 Affymax Technologies Nv Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof
US5780426A (en) 1995-06-07 1998-07-14 Ixsys, Incorporated Fivemer cyclic peptide inhibitors of diseases involving αv β3
US5569588A (en) 1995-08-09 1996-10-29 The Regents Of The University Of California Methods for drug screening
US7053041B1 (en) * 1996-05-31 2006-05-30 The Scripps Research Institute Methods and compositions useful for inhibition of αvβ5mediated angiogenesis
DE69635417T2 (de) * 1995-08-14 2006-07-13 The Scripps Research Institute, La Jolla VERFAHREN UND MITTEL ZUR HEMMUNG DER DURCH ALPHA v BETA 5 VERMITTELTEN ANGIOGENESE
JP2002504086A (ja) 1996-05-01 2002-02-05 イーライ・リリー・アンド・カンパニー Ｖｅｇｆ関連疾患の治療的処置
ES2286834T5 (es) 1996-08-12 2011-01-31 Mitsubishi Tanabe Pharma Corporation Medicamentos que comprenden un inhibidor de la rho quinasa.
UA60311C2 (uk) * 1996-10-02 2003-10-15 Смітклайн Бічам Корпорейшн Антагоністи рецептора вітронектину, спосіб одержання цих сполук та фармацевтична композиція
CO4920232A1 (es) * 1997-01-08 2000-05-29 Smithkline Beecham Corp Acidos aceticos dibenzo [a,d] cicloheptano con actividad antagonista del receptor de vitronectin
TW589189B (en) 1997-08-04 2004-06-01 Scras Kit containing at least one double-stranded RNA combined with at least one anti-viral agent for therapeutic use in the treatment of a viral disease, notably of viral hepatitis
US20020004482A1 (en) * 1997-08-08 2002-01-10 Xiaozhu Huang Treatment of acute lung injury and fibrosis with antagonists of avbeta6
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
GB9827152D0 (en) 1998-07-03 1999-02-03 Devgen Nv Characterisation of gene function using double stranded rna inhibition
DE19842415A1 (de) 1998-09-16 2000-03-23 Merck Patent Gmbh Pharmazeutische Zubereitung
ATE477273T1 (de) 1998-12-01 2010-08-15 Facet Biotech Corp Humanisierte antikoerper gegen gamma-interferon
EP1140205A2 (en) 1998-12-30 2001-10-10 Edema Clearance, Inc. GENE THERAPY FOR PULMONARY EDEMA USING ADENOVIRUS VECTORS ENCODING Na,K-ATPase
WO2000044914A1 (en) 1999-01-28 2000-08-03 Medical College Of Georgia Research Institute, Inc. Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna
DE19956568A1 (de) 1999-01-30 2000-08-17 Roland Kreutzer Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
US6399581B1 (en) 1999-05-11 2002-06-04 Harbor Branch Oceanographic Institution, Inc. Compound possessing potent thrombin receptor antagonist activity
DE60021521T4 (de) 1999-09-29 2006-09-21 Ortho-Mcneil Pharmaceutical, Inc. Isonipecotamide zur behandlung von integrin vermittelten störungen
HK1047109A1 (zh) 1999-10-15 2003-02-07 University Of Massachusetts 作为指定基因干预工具的rna干预轨迹基因
US6544982B1 (en) 1999-10-29 2003-04-08 Merck & Co., Inc. Thrombin receptor antagonists
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
AU780364B2 (en) 2000-01-20 2005-03-17 Merck Sharp & Dohme Corp. Alpha V integrin receptor antagonists
CA2397665A1 (en) 2000-01-24 2001-07-26 Merck & Co., Inc. Alpha v integrin receptor antagonists
US6515023B2 (en) 2000-01-31 2003-02-04 Merck & Co., Inc. Thrombin receptor antagonists
US6403612B2 (en) 2000-01-31 2002-06-11 Merck & Co., Inc. Thrombin receptor antagonists
ES2341843T3 (es) 2000-02-03 2010-06-29 EISAI R&D MANAGEMENT CO., LTD. Inhibidores de la expresion de integrina.
US6518244B2 (en) 2000-03-09 2003-02-11 Intimax Corporation Combinations of heparin cofactor II agonist and platelet IIb/IIIa antagonist, and uses thereof
JP2001320372A (ja) 2000-03-13 2001-11-16 Hyundai Electronics Ind Co Ltd 統合インターネットプロトコル網で統合加入者サーバの機能的モデリングを通した統合加入者管理装置及びその方法
WO2001078790A2 (en) 2000-04-18 2001-10-25 Edema Clearance, Inc. GENE THERAPHY FOR PULMONARY EDEMA USING ADENOVIRUS VECTORS ENCODING A β2ADRENERGIC RECEPTOR GENE
EP1289960A2 (en) 2000-06-15 2003-03-12 Pharmacia Corporation Cycloalkyl alkanoic acids as integrin receptor antagonists
US7288390B2 (en) * 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
DE10041423A1 (de) 2000-08-23 2002-03-07 Merck Patent Gmbh Biphenylderivate
US20020072500A1 (en) 2000-09-27 2002-06-13 Thomas Rogers Hydroxy acid integrin antagonists
JP2004513953A (ja) 2000-10-24 2004-05-13 メルク　エンド　カムパニー　インコーポレーテッド ジベンズオキサゼピンαＶインテグリン受容体アンタゴニスト
CA2433680A1 (en) 2000-12-28 2002-08-01 Gregory M Arndt Double-stranded rna-mediated gene suppression
JP2005506524A (ja) 2001-04-04 2005-03-03 アラーガン、インコーポレイテッド 血管新生の阻害剤をスクリーニングおよび使用する方法
US7081460B2 (en) 2001-04-09 2006-07-25 Ortho-Mcneil Pharmaceutical, Inc. Quinazoline and quinazoline-like compounds for the treatment of integrin-mediated disorders
US20040019206A1 (en) 2001-09-27 2004-01-29 Peter Ruminiski Lactone integrin antagonists
DK1539739T3 (da) * 2002-08-16 2011-03-07 Janssen Pharmaceutica Nv Piperidinylforbindelser, der selektivt binder integriner
US20040266755A1 (en) 2003-05-29 2004-12-30 Schering Aktiengesellschaft Prodrugs of 1-(1-hydroxy-5-isoquinolinesulfonyl) homopiperazine
JO3421B1 (ar) 2011-06-20 2019-10-20 H Lundbeck As طريقة لإعطاء 1-((1ار.3س)-6-كلورو-3-فينيل-اندان-1-ايل)-1.2.2-ترايميثيل- بيبيرازين واملاجها لمعالجة انفصام الشخصية

Also Published As

Publication number Publication date
ES2411965T3 (es) 2013-07-09
JP5681149B2 (ja) 2015-03-04
JP2007531733A (ja) 2007-11-08
EP2394662B1 (en) 2018-03-21
WO2005094391A2 (en) 2005-10-13
ES2671522T3 (es) 2018-06-06
US20050226865A1 (en) 2005-10-13
AU2005229015A1 (en) 2005-10-13
AU2005229015B2 (en) 2012-08-30
CA2562038C (en) 2017-04-25
HK1098077A1 (en) 2007-07-13
WO2005094391A3 (en) 2005-12-01
PT1734996E (pt) 2013-07-18
CN1964740A (zh) 2007-05-16
EP2394662A2 (en) 2011-12-14
EP1734996A4 (en) 2008-09-10
HRP20130782T1 (en) 2013-09-30
EP2394662A3 (en) 2012-02-22
RS52918B (sr) 2014-02-28
CA2562038A1 (en) 2005-10-13
DK1734996T3 (da) 2013-06-10
EP1734996B1 (en) 2013-05-22
EP1734996A2 (en) 2006-12-27
JP2013028611A (ja) 2013-02-07
US7815908B2 (en) 2010-10-19
PL1734996T3 (pl) 2013-09-30
US20090280118A1 (en) 2009-11-12
AU2005229015C1 (en) 2013-01-17
JP5223072B2 (ja) 2013-06-26

Similar Documents

Publication Publication Date Title
CY1114497T1 (el) ΜΕΘΟΔΟΙ ΚΑΙ ΣΥΝΘΕΣΕΙΣ ΓΙΑ ΤΗΝ ΑΝΤΙΜΕΤΩΠΙΣΗ ΚΑΙ ΤΗΝ ΠΡΟΛΗΨΗ ΝΟΣΟΥ ΠΟΥ ΣΧΕΤΙΖΕΤΑΙ ΜΕ ΤΗΝ ΙΝΤΕΓΚΡΙΝΗ ανβ5
CY1121162T1 (el) M-csf-ειδικο μονοκλωνικο αντισωμα και χρησεις αυτου
CY1113963T1 (el) Φαρμακευτικες συνθεσεις οι οποιες περιλαμβανουν ανταγωνιστες ακτιβινης-actriia και χρηση αυτων στην προληψη η' θεραπευτικη αγωγη πολλαπλου μυελωματος
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
TR200906131T1 (tr) Aktivin -actrIIa antagonistleri ve göğüs kanserinin tedavi e
CY1118523T1 (el) Πεπτιδικες ενωσεις για την θεραπεια του ανθεκτικου status epilepticus
MX2009012625A (es) Metodos para el tratamiento, diagnostico y deteccion de trastornos asociados con el fgf21.
CY1119601T1 (el) Προαγωγεις αποπτωσης
MA30153B1 (fr) Anticorps anti-ox40l et methodes correspondantes
ATE538650T1 (de) Cannabinoid-rezeptor-antagonisten / inverse agonisten zur behandlung von übergewicht
CY1109741T1 (el) Sns-595 και μεθοδοι χρησης αυτου
NO20083397L (no) Anti-EphB4-antistoffer og fremgangsmater for anvendelse av disse
CY1113192T1 (el) Ενωσεις και μεθοδοι για την αναστολη της μιτωτικης προοδου μεσω αναστολης της κινασης aurora
DK1773885T3 (da) Humaniserede anti-c-met-antagonister
ATE554114T1 (de) Copolymer mit zwitterionischen einheiten und anderen einheiten, das copolymer umfassende zusammensetzung und verwendung
PH12015500550A1 (en) Anti-notch1 nrr antibodies and methods using same
CY1118231T1 (el) Συνθεση λιποσωματος
MX2009000285A (es) Piperidinas sustituidas que incrementan la actividad de p53 y usos de las mismas.
CY1113640T1 (el) Μεθοδοι για την θεραπευτικη αγωγη ρευματοειδους αρθριτιδας
ATE469895T1 (de) Cgrp-rezeptorantagonisten
ECSP088529A (es) Anticuerpos anti mn y métodos para su utilización
CY1109010T1 (el) γ-ΚΡΥΣΤΑΛΛΙΚΗ ΜΟΡΦΗ ΤΗΣ ΥΔΡΟΧΛΩΡΙΚΗΣ ΙΒΑΒΡΑΔΙΝΗΣ, ΜΕΘΟΔΟΣ ΠΑΡΑΣΚΕΥΗΣ ΤΗΣ ΚΑΙ ΦΑΡΜΑΚΕΥΤΙΚΕΣ ΣΥΝΘΕΣΕΙΣ ΠΟΥ ΤΗΝ ΠΕΡΙΕΧΟΥΝ
DK3530673T3 (da) Humaniserede anti-beta7-antagonister og anvendelser deraf
CY1108843T1 (el) 3,11β cis διϋδροτετραβεναζινη για την θεραπεια της σχιζοφρενιας και αλλων ψυχωσεων
CY1115919T1 (el) Ενωσεις ενεργοποιησης τελομερασης και μεθοδοι χρησης αυτων